These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 28993206)

  • 1. Targeting receptor tyrosine kinase EphB4 in cancer therapy.
    Chen Y; Zhang H; Zhang Y
    Semin Cancer Biol; 2019 Jun; 56():37-46. PubMed ID: 28993206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biological Significance of EphB4 Expression in Cancer.
    Ullah A; Razzaq A; Zhou C; Ullah N; Shehzadi S; Aziz T; Alfaifi MY; Elbehairi SEI; Iqbal H
    Curr Protein Pept Sci; 2024; 25(3):244-255. PubMed ID: 37909437
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EphB4: A promising target for upper aerodigestive malignancies.
    Salgia R; Kulkarni P; Gill PS
    Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):128-137. PubMed ID: 29369779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The small molecule specific EphB4 kinase inhibitor NVP-BHG712 inhibits VEGF driven angiogenesis.
    Martiny-Baron G; Holzer P; Billy E; Schnell C; Brueggen J; Ferretti M; Schmiedeberg N; Wood JM; Furet P; Imbach P
    Angiogenesis; 2010 Sep; 13(3):259-67. PubMed ID: 20803239
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ephrin-independent regulation of cell substrate adhesion by the EphB4 receptor.
    Noren NK; Yang NY; Silldorff M; Mutyala R; Pasquale EB
    Biochem J; 2009 Aug; 422(3):433-42. PubMed ID: 19552627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interplay between EphB4 on tumor cells and vascular ephrin-B2 regulates tumor growth.
    Noren NK; Lu M; Freeman AL; Koolpe M; Pasquale EB
    Proc Natl Acad Sci U S A; 2004 Apr; 101(15):5583-8. PubMed ID: 15067119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-based optimization of potent and selective inhibitors of the tyrosine kinase erythropoietin producing human hepatocellular carcinoma receptor B4 (EphB4).
    Lafleur K; Huang D; Zhou T; Caflisch A; Nevado C
    J Med Chem; 2009 Oct; 52(20):6433-46. PubMed ID: 19788238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The EphB4 receptor tyrosine kinase promotes lung cancer growth: a potential novel therapeutic target.
    Ferguson BD; Liu R; Rolle CE; Tan YH; Krasnoperov V; Kanteti R; Tretiakova MS; Cervantes GM; Hasina R; Hseu RD; Iafrate AJ; Karrison T; Ferguson MK; Husain AN; Faoro L; Vokes EE; Gill PS; Salgia R
    PLoS One; 2013; 8(7):e67668. PubMed ID: 23844053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EphB4 promotes or suppresses Ras/MEK/ERK pathway in a context-dependent manner: Implications for EphB4 as a cancer target.
    Xiao Z; Carrasco R; Kinneer K; Sabol D; Jallal B; Coats S; Tice DA
    Cancer Biol Ther; 2012 Jun; 13(8):630-7. PubMed ID: 22555806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PDGFRβ reverses EphB4 signaling in alveolar rhabdomyosarcoma.
    Aslam MI; Abraham J; Mansoor A; Druker BJ; Tyner JW; Keller C
    Proc Natl Acad Sci U S A; 2014 Apr; 111(17):6383-8. PubMed ID: 24733895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EphB4 forward signalling regulates lymphatic valve development.
    Zhang G; Brady J; Liang WC; Wu Y; Henkemeyer M; Yan M
    Nat Commun; 2015 Apr; 6():6625. PubMed ID: 25865237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis and characterization of novel small molecular inhibitors of ephrin-B2 binding to EphB4.
    Duggineni S; Mitra S; Noberini R; Han X; Lin N; Xu Y; Tian W; An J; Pasquale EB; Huang Z
    Biochem Pharmacol; 2013 Feb; 85(4):507-13. PubMed ID: 23253822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure and thermodynamic characterization of the EphB4/Ephrin-B2 antagonist peptide complex reveals the determinants for receptor specificity.
    Chrencik JE; Brooun A; Recht MI; Kraus ML; Koolpe M; Kolatkar AR; Bruce RH; Martiny-Baron G; Widmer H; Pasquale EB; Kuhn P
    Structure; 2006 Feb; 14(2):321-30. PubMed ID: 16472751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of Ephb2 and Ephb4 in breast carcinoma.
    Wu Q; Suo Z; Risberg B; Karlsson MG; Villman K; Nesland JM
    Pathol Oncol Res; 2004; 10(1):26-33. PubMed ID: 15029258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pancreatic Tumor Microenvironment Modulation by EphB4-ephrinB2 Inhibition and Radiation Combination.
    Lennon S; Oweida A; Milner D; Phan AV; Bhatia S; Van Court B; Darragh L; Mueller AC; Raben D; Martínez-Torrecuadrada JL; Pitts TM; Somerset H; Jordan KR; Hansen KC; Williams J; Messersmith WA; Schulick RD; Owens P; Goodman KA; Karam SD
    Clin Cancer Res; 2019 Jun; 25(11):3352-3365. PubMed ID: 30944125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Pyrazolo[3,4-
    Neuber C; Tröster A; Löser R; Belter B; Schwalbe H; Pietzsch J
    Molecules; 2020 Nov; 25(21):. PubMed ID: 33153234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fluorine-18 radiolabeling and radiopharmacological characterization of a benzodioxolylpyrimidine-based radiotracer targeting the receptor tyrosine kinase EphB4.
    Mamat C; Mosch B; Neuber C; Köckerling M; Bergmann R; Pietzsch J
    ChemMedChem; 2012 Nov; 7(11):1991-2003. PubMed ID: 23042640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overexpression of Receptor Tyrosine Kinase EphB4 Triggers Tumor Growth and Hypoxia in A375 Melanoma Xenografts: Insights from Multitracer Small Animal Imaging Experiments.
    Neuber C; Belter B; Meister S; Hofheinz F; Bergmann R; Pietzsch HJ; Pietzsch J
    Molecules; 2018 Feb; 23(2):. PubMed ID: 29462967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aberrant DNA methylation and epigenetic inactivation of Eph receptor tyrosine kinases and ephrin ligands in acute lymphoblastic leukemia.
    Kuang SQ; Bai H; Fang ZH; Lopez G; Yang H; Tong W; Wang ZZ; Garcia-Manero G
    Blood; 2010 Mar; 115(12):2412-9. PubMed ID: 20061560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of receptor tyrosine kinase EphB4 and its ligand ephrin-B2 is associated with malignant potential in endometrial cancer.
    Takai N; Miyazaki T; Fujisawa K; Nasu K; Miyakawa I
    Oncol Rep; 2001; 8(3):567-73. PubMed ID: 11295082
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.